# Omer Zaidi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/omer-zaidi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 148 |
| Field | Pneumonia and Respiratory Infections |
| h-index | 7 |
| i10-index | 6 |
| Last Known Institution | The Open Group |
| OpenAlex ID | https://openalex.org/A5058812106 |
| ORCID iD | 0000-0002-3187-9316 |
| Works | 26 |

## Researcher papers

- [Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction](https://scholariq.org/papers/factors-associated-with-non-use-and-sub-target-dosing-of-medical-therapy-for/)
- [Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries](https://scholariq.org/papers/review-on-epidemiology-disease-burden-and-treatment-patterns-of-iga-nephropathy/)
- [The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR)](https://scholariq.org/papers/the-real-world-incidence-of-relapse-in-acute-myeloid-leukemia-aml-a-systematic/)
- [Systematic literature review of the disease burden and vaccination of pneumococcal disease among adults in select Asia-Pacific areas](https://scholariq.org/papers/systematic-literature-review-of-the-disease-burden-and-vaccination-of/)
- [Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data](https://scholariq.org/papers/biosimilar-pegfilgrastim-may-offer-affordable-treatment-options-for-patients-in/)
- [A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.](https://scholariq.org/papers/a-systematic-literature-review-of-disease-burden-and-clinical-efficacy-for/)
- [Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region](https://scholariq.org/papers/integrative-literature-review-on-human-papillomavirus-vaccination/)
- [Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia](https://scholariq.org/papers/real-world-cost-effectiveness-of-primary-prophylaxis-with-g-csf-biosimilars-in/)
- [Current Treatment Paradigms and Clinical Outcomes in Oligometastatic Prostate Cancer Patients: A Targeted Literature Review](https://scholariq.org/papers/current-treatment-paradigms-and-clinical-outcomes-in-oligometastatic-prostate/)
- [Systematic literature review on the clinical and economic burden of human papillomavirus–related diseases in select areas in the Asia-Pacific region](https://scholariq.org/papers/systematic-literature-review-on-the-clinical-and-economic-burden-of-human/)

## Researcher topics

- [Pneumonia and Respiratory Infections](https://scholariq.org/topics/pneumonia-and-respiratory-infections/)
- [Influenza Virus Research Studies](https://scholariq.org/topics/influenza-virus-research-studies/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Respiratory viral infections research](https://scholariq.org/topics/respiratory-viral-infections-research/)
- [Cervical Cancer and HPV Research](https://scholariq.org/topics/cervical-cancer-and-hpv-research/)

## Researcher university

- [The Open Group](https://scholariq.org/institutions/the-open-group/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.